AU2021241899A1 - Split inteins and their uses - Google Patents

Split inteins and their uses Download PDF

Info

Publication number
AU2021241899A1
AU2021241899A1 AU2021241899A AU2021241899A AU2021241899A1 AU 2021241899 A1 AU2021241899 A1 AU 2021241899A1 AU 2021241899 A AU2021241899 A AU 2021241899A AU 2021241899 A AU2021241899 A AU 2021241899A AU 2021241899 A1 AU2021241899 A1 AU 2021241899A1
Authority
AU
Australia
Prior art keywords
fragment
intein
degron
protein
directly linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021241899A
Other languages
English (en)
Inventor
Gerard CAELLES VIDAL
Silvia FRUTOS DOMÍNGUEZ
Anabel OTERO BILBAO
Miquel VILA PERELLÓ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Splicebio SL
Original Assignee
Splicebio SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Splicebio SL filed Critical Splicebio SL
Publication of AU2021241899A1 publication Critical patent/AU2021241899A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021241899A 2020-03-26 2021-03-26 Split inteins and their uses Pending AU2021241899A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382236.6A EP3885440A1 (en) 2020-03-26 2020-03-26 Split inteins and their uses
EP20382236.6 2020-03-26
PCT/EP2021/058016 WO2021191447A1 (en) 2020-03-26 2021-03-26 Split inteins and their uses

Publications (1)

Publication Number Publication Date
AU2021241899A1 true AU2021241899A1 (en) 2022-10-06

Family

ID=70292931

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021241899A Pending AU2021241899A1 (en) 2020-03-26 2021-03-26 Split inteins and their uses

Country Status (10)

Country Link
US (1) US20230116688A1 (cg-RX-API-DMAC7.html)
EP (2) EP3885440A1 (cg-RX-API-DMAC7.html)
JP (1) JP7867703B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220160052A (cg-RX-API-DMAC7.html)
CN (1) CN115698307A (cg-RX-API-DMAC7.html)
AU (1) AU2021241899A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019167A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175696A1 (cg-RX-API-DMAC7.html)
IL (1) IL296712A (cg-RX-API-DMAC7.html)
WO (1) WO2021191447A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
WO2021040703A1 (en) * 2019-08-28 2021-03-04 The Trustees Of Princeton University Atypical split inteins and uses thereof
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
US20250319126A1 (en) * 2021-10-29 2025-10-16 Shanghai Sinobay Biotechnology Co., Ltd. Condition-controlled spliceable chimeric antigen receptor molecule and application thereof
CN117106824B (zh) * 2022-05-17 2025-09-02 上海佑音医药生物科技有限公司 一种治疗听力损伤的双载体系统及其应用
KR20250141200A (ko) * 2023-02-01 2025-09-26 알렌 인스티튜트 전압-게이팅 나트륨 채널 기능의 인테인 매개 재구성
EP4726045A1 (en) 2023-06-07 2026-04-15 Peking University Third Hospital (The Third Clinical Medical School of Peking University) Expression cassette combination and use thereof
EP4762183A1 (en) * 2023-08-16 2026-06-24 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Systems and methods for improving safety of split intein aav mediated gene therapy
CN121909039A (zh) 2023-09-04 2026-04-21 斯普莱斯生物有限责任公司 分裂内含肽用于治疗scn1a相关疾病的用途
WO2025153705A1 (en) 2024-01-18 2025-07-24 Splicebio, Sl Use of split intein for the treatment of myo7a-associated disease
WO2025193938A1 (en) * 2024-03-13 2025-09-18 Oregon Health & Science University Delivery of type iv collagen alpha chain using a split intein dual aav vector
WO2026013288A1 (en) 2024-07-12 2026-01-15 Splicebio, Sl Split intein for use in the treatment of cep290-associated disease
WO2026057767A1 (en) 2024-09-13 2026-03-19 Splicebio, Sl Use of split intein for the treatment of abca3-associated disease
WO2026109723A1 (en) * 2024-11-22 2026-05-28 Katholieke Universiteit Leuven Efficient intein splicing in dual aav gene delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US8298818B2 (en) 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
CA2979120A1 (en) * 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
SG11201710569YA (en) * 2015-06-19 2018-01-30 Riken pH-RESPONSIVE PROTEOLYSIS PROBE
WO2017132580A2 (en) * 2016-01-29 2017-08-03 The Trustees Of Princeton University Split inteins with exceptional splicing activity
CA3116606A1 (en) 2018-10-15 2020-04-23 Fondazione Telethon Intein proteins and uses thereof

Also Published As

Publication number Publication date
EP4127194A1 (en) 2023-02-08
EP3885440A1 (en) 2021-09-29
JP7867703B2 (ja) 2026-06-01
WO2021191447A1 (en) 2021-09-30
CA3175696A1 (en) 2021-09-30
CN115698307A (zh) 2023-02-03
IL296712A (en) 2022-11-01
BR112022019167A2 (pt) 2022-11-01
KR20220160052A (ko) 2022-12-05
JP2023518596A (ja) 2023-05-02
US20230116688A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
WO2021191447A1 (en) Split inteins and their uses
CN113631182B (zh) 二硫键稳定的多肽组合物和使用方法
CN114127089A (zh) 重组腺相关病毒及其用途
CN110461368A (zh) 具有变异衣壳的腺相关病毒病毒体及其使用方法
JP2025508677A (ja) ポンペ病の処置のための抗TfR:GAA及び抗CD63:GAAの挿入
CN114008069A (zh) 外来体和aav的组合物
CN107466325A (zh) 多重载体系统及其应用
CN111718418B (zh) 一种增强基因编辑的融合蛋白及其应用
US20260055144A1 (en) Recombinant adeno-associated viruses and uses thereof
JP2025514631A (ja) Cns症状を有する疾患の遺伝子治療
KR20210040984A (ko) 점액다당류증 iva의 치료
US20210047657A1 (en) Methods of aav vector production by modulating deubiquitinating enzyme activity
EP4729620A1 (en) Gene therapy vector for treating parkinson's disease and use thereof
EP4493226A1 (en) Modified muscle-specific promoters
US20260115322A1 (en) Recombinant tert-encoding viral genomes and vectors
JP2024517957A (ja) ベクター系
WO2021080975A1 (en) Compositions and methods for reducing cholesterol levels
US7122348B2 (en) AAV2 Rep protein fusions
EP4516805A1 (en) Viral vector for fibroblast transfection
WO2024216244A9 (en) Targeting aav capsids, methods of manufacturing and using same
WO2026057767A1 (en) Use of split intein for the treatment of abca3-associated disease
HK40053744B (en) Disulfide bond stabilized polypeptide compositions and methods of use
WO2024044691A9 (en) Modified aav vectors for gene therapy
HK40053744A (zh) 二硫键稳定的多肽组合物和使用方法
HK40063598A (en) Enpp1 polypeptides and methods of using same